| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $460.2M | +15.3% |
| Cost of Revenue | $190.5M | +29.5% |
| R&D Expense | $220.9M | -5.8% |
| SG&A Expense | $277.6M | -7.1% |
| Operating Income | -$229.4M | +18.7% |
| Pre-tax Income | -$178.5M | +30.6% |
| Income Tax | -$2.9M | — |
| Net Income | -$175.5M | +31.7% |
| EPS (Basic) | -$0.16 |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $679.6M | +51.1% |
| Short-term Investments | $10.0M | -97.0% |
| Accounts Receivable | $106.1M | +24.6% |
| Inventory | $74.7M | +87.4% |
| Current Assets | $1.02B | -3.0% |
| Total Assets | $1.17B | -1.1% |
| Current Liabilities | $416.2M | +39.0% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$150.8M | +29.8% |
| Capital Expenditures | $8.1M | +43.2% |
| Investing Cash Flow | $307.9M | +182.1% |
| Financing Cash Flow | $72.4M | -79.3% |
| Free Cash Flow | -$158.9M | +27.9% |
| +38.5% |
| EPS (Diluted) | -$0.16 | +38.5% |
| Total Liabilities |
| $456.9M |
| +32.5% |
| Stockholders' Equity | $715.5M | -14.9% |